Mizagliflozin (DSP-3235 free base) is a potent, orally active, and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. It displays 303-fold selectivity over SGLT2. This compound functions as an antidiabetic agent capable of modifying postprandial blood glucose excursion and also shows potential in the amelioration of chronic constipation. In vivo, the compound at doses of 3-30 mg/kg orally has a laxative effect, increasing fecal wet weight in a rat model of low-fiber-diet-induced constipation. The compound has a short half-life, with 0.23 h after intravenous administration and 1.14 h after oral administration.
- Highly selective SGLT1 inhibitor
- Helps manage postprandial blood glucose levels
- Potential to treat chronic constipation
- Orally active for convenient administration